Background: While pediatric low-grade glioma/glioneuronal tumors (LGG/LGGNTs) are considered slow-growing, indolent tumors with excellent long-term prognosis, mortality due to the disease is not unknown. Few studies have addressed the cause of death in this population. Results: For the 87 eligible patients, median age at diagnosis was 7.7 years (range, 0.21-21 years), median age at death was 14.26 years (range, 0.58-32 years), and median time to death from diagnosis was 4.02 years (range, 0.21-24 years). Midbrain/thalamus was the most common tumor location (n = 34), followed by suprasellar/hypothalamic (n = 18) and cerebrocortical (n = 13).
INTRODUCTION
Pediatric low-grade gliomas (LGGs) and low-grade glioneuronal tumors (LGGNTs) (WHO Grade I & II tumors) generally have excellent outcomes with prolonged survival, especially when a gross total resection (GTR) of the tumor is achieved. [1] [2] [3] [4] [5] LGG/LGGNTs are often viewed as a chronic disease with an indolent course, in contrast to some other central nervous system (CNS) malignancies (e.g., embryonal tumors or Abbreviations: GTR, gross total resection; HGG, high-grade glioma; LGG, low-grade glioma;
LGGNTs, low-grade glioneuronal tumors; MT, malignant transformation; NF-1, neurofibromatosis type I; NTR, near total resection; PD, progressive disease; PD-HGG, progressive disease with high-grade glioma at progression; PET, positron emission tomography; RT, radiation therapy; STR, subtotal resection high-grade gliomas [HGGs] ). Children with LGG/LGGNT often require multiple treatment regimens to halt tumor progression. 6, 7 A vast majority survive into adulthood, but a small proportion ultimately succumb. The reported rate of mortality in children with LGG/LGGNT is 5-18%. 1, 2, 4, 8, 9 The causes of mortality include, but are not limited to, progression of primary disease (PD), pathologic progression to HGG, and treatment-associated complications. [8] [9] [10] Barring a few studies, there is a scarcity of literature on the causes of death of these children and the clinicopathologic variables that may predict a fatal outcome. 8, 9 In an attempt to systematically delineate the causes and timing of mortality in this population, we undertook a retrospective study of children with
LGG/LGGNT who died during the course of their treatment or followup at St. Jude Children's Research Hospital (St. Jude).
METHODS

Study design
We conducted a retrospective review of the medical records of all children with a WHO Grade I or II LGG/LGGNT, who were 21 years or younger at diagnosis and had died during the course of their treatment or follow-up at St. Jude. The study period was April 1985 to June 2015.
The date of first presentation at St. Jude was considered the study entry point. Patients were included in the study if they had a histologic confirmation of a WHO Grade I or II LGG/LGGNT or in the presence of corroborative tumor-related symptoms, an imaging finding compatible with WHO Grade I or II LGG/
LGGNT. An example of the latter is visual impairment in children with optic nerve lesion, in whom the diagnosis of LGG is often made without biopsy. The data collected included patient demographics, tumor location and histology, metastatic status, number and type of treatments received, the cause of mortality, and time to death from diagnosis. This study was approved by the St. Jude Institutional Review Board.
The date of first imaging, when available, was considered the date of diagnosis. If that data were not available, then the date of first biopsy or tumor resection and histologic confirmation of LGG/LGGNT was considered the date of diagnosis. The cause of death was ascertained from the medical record or death certificate. The treatments administered were categorized as surgical resection, chemotherapy, or radiation therapy (RT).
Surgical outcomes
The extent of surgical resection was determined by the operating surgeon, imaging results, or both. The categories of surgical resection were defined as follows: GTR, when no tumor remained visible in the surgical field; near-total resection (NTR), when more than 90% of the tumor was removed; subtotal resection (STR), when 50-90% of the tumor was removed; and partial resection (PR), when less than 50% of the tumor was removed. When the surgical intent was to obtain tumor tissue for diagnosis without any effort to resect the tumor, it was termed biopsy only.
Other treatments
Chemotherapy regimens varied, depending on the availability of ongoing clinical trials or nonprotocol treatment plans, from singleagent therapy (e.g., parenteral cyclophosphamide or oral temozolamide) to the more traditional combination chemotherapy (e.g., vincristine/carboplatin). RT was either focal, whole-brain, or craniospinal irradiation. When more than one treatment modality was used at diagnosis or each progression, it was counted as a single regimen.
Causes of and time to death
Time to death was calculated as the period from the time of diagnosis to that of mortality. The causes of mortality were classified as follows: PD, progression of PD with histological features of an HGG at progression or autopsy (PD-HGG), second malignancy (i.e., when the second tumor was noncontiguous in location and/or histologically different from the primary LGG/LGGNT), therapy-induced or tumor location associated complications, and miscellaneous causes. A diagnosis of PD-HGG was made based on clinical suspicion of progression and when corroborating histologic confirmation of LGG/LGGNT at diagnosis and that of an HGG at progression or on autopsy was available.
Statistical methods
Descriptive statistics were used to designate the distributions of variables of interest. The results are presented as median, range, and percentages.
RESULTS
Patient characteristics
Of the 727 patients with LGG/LGGNT treated at our institution during the study period, 87 (12%) died during treatment or follow-up. Among the 727 patients, 370 patients had their domiciliary residence in Memphis and adjoining cities, for which St. Jude is the primary tertiary hospital of care. The remaining 357 patients were referred from other institutions to St. Jude. Among those who died from the disease, 42 patients were from the Memphis geographic location while 45 were referred to St. Jude for care. All 87 subjects were included in this study.
The median age of the cohort at diagnosis was 7.7 years (range, 0.21-21 years). There was a predominance of male patients in our study, with a male-to-female ratio of 1.7:1 (Table 1) . Two-thirds of our patients (n = 59) identified as white race; about one-third identified as black race (n = 24); one patient identified as mixed race; and three identified as other. Three patients had a diagnosis of neurofibromatosis type 1 (NF-1).
Tumor location, histology, and metastasis
The midbrain and/or thalamus was the most common location of the tumor, being found in 39% (n = 34) of the cases. This was followed by the suprasellar/hypothalamic area in 21% (n = 18) of patients and cerebrocortical and brain stem distribution in approximately 15% (n = 13) and 14% (n = 12), respectively (Table 1, Fig. 1 ). Other primary tumors were located in the tectum (n = 3), cerebellum (n = 2), cervicomedullary (n = 1), and spine (n = 4). Histopathology data were available for 93% (n = 81) of the patients, and all tissue samples were reviewed at our institution, except for that of one patient who had PD-HGG and for whom the high-grade pathology was unavailable for review. The three most common diagnoses included astrocytoma not otherwise specified (28%, n = 24), pilocytic astrocytoma (26%, n = 23), and diffuse fibrillary astrocytoma (13%, n = 11). Remaining tumors included oligodendroglioma/oligoastrocytoma (n = 7), pleomorphic xanthoastrocytoma (n = 6), ganglioglioma (n = 4), glioma not otherwise specified (n = 4), desmoplastic infantile ganglioglioma (n = 1), and glioneural tumor (n = 1). LGG, alive or dead, reported from our institution by Chamdine et al. 11 All patients had at least one imaging examination (either computed tomography or MRI) to investigate for dissemination. Thirty (34%) patients had imaging evidence of disease spread to a site distant from the primary tumor location during the course of their illness (Table 1) .
TA B L E 1
Causes of mortality and time to death
PD refractory to treatment was the most common cause of death in our study population; 43 (49%) children succumbed to disease. PD-HGG was the second most common cause of death, occurring in 15 (17%) patients. All 15 patients had a histologic confirmation of a HGG, with tissue samples available at diagnosis and progression or autopsy.
Glioblastoma was the most common diagnosis at the time of progression or on autopsy in these 15 patients (Table 2) .
We hypothesized that some tumors with PD-HGG were second malignancies. The images and tissue-sampling sites at diagnosis and at progression/autopsy were further analyzed for these 15 patients.
We found that in 12 of 15 patients the location of the primary tumor and tumor at progression were unequivocally identical or contiguous (Table 2 ). The same was true for the site of tissue sampling at diagnosis and progression or autopsy. However, in three patients (13, 14, and 15; Table 2 ), the sites of sampling the primary tumor and that of progression were noncontiguous, albeit very close to each other, raising the possibility of those tumors being second malignancies (Fig. 2) .
Three patients died of second malignancy. Two of the three patients had NF-1: malignant peripheral nerve sheath tumor developed in one, and medulloblastoma developed in the other. The third patient suffered refractory T-cell acute lymphoblastic leukemia. The other tumorrelated causes of death included shunt infection and sepsis (n = 3) and respiratory compromise due to a brainstem location of the tumor (n = 3). Two patients committed suicide; one patient's reason for the act was anxiety and apprehension about PD. Miscellaneous causes of death included aspiration pneumonia and adult respiratory distress syndrome (n = 2), stroke (n = 2), renal toxicity due to chemotherapy (n = 1), endocardial fibrosis (n = 1), tumor hemorrhage (n = 1), and pontine demyelination (n = 1). Two patients died in motor vehicle accidents.
The cause of death was obtained from death certificates for eight patients and included suicide (n = 2), motor vehicle accident (n = 1), hydrocephalus due to shunt failure (n = 1), and PD (n = 4). The precise details of the events leading to death were lacking in these cases;
hence, we listed them separately. The four patients whose deaths were documented as due to PD were not included in the analysis of time to death for those with PD due to a lack of sufficient information pertaining to their deaths.
The median age at death for the cohort was 14.26 years (range, 0.58-32 years), and the median time to death from diagnosis was (Table 4) .
Treatment details
Our patients underwent surgical resection, chemotherapy, RT, or a combination thereof. The median number of treatments received was two (range, 0-6), and 20 (23%) patients received four or more therapies. Although 12 of 15 patients who had PD-HGG received RT during the course of their illness, four had confirmation of HGG only upon autopsy. Therefore, these four patients may have already progressed to HGG before receiving RT. In the remaining eight patients, RT was administered at variable times before histologic confirmation of HGG.
Of the remaining 72 patients, 45 received RT but had no histologically documented HGG.
DISCUSSION
Despite its overall good prognosis, LGG/LGGNT in children can result in mortality, either due to tumor-related causes or complications arising from therapeutic intervention(s). 1, 4, 8, 9 In this single-institution More than half of the patients in our study who died of PD did so within 2 years of diagnosis. Thirty one of the 43 children who died of PD had undergone only a biopsy for histologic confirmation of LGG at diagnosis. Biopsies sometimes miss areas of high-grade tumor due to the limited availability of tissue sample. However, we thought it was necessary to understand the cause of death in patients with biopsyonly evidence of LGG/LGGNT, because in a substantial proportion of patients this is the only way to determine the histology and grade of tumor, as a more extensive resection is not possible due to the tumor's location. Hence, we included these patients in our study to determine whether their causes of death were similar to those in previous studies of LGG outcome. 4, 14 This raises an important concern that clin- PD-HGG, progressive disease with high-grade glioma at progression; CP, cerebellar peduncle ;GB, glioblastoma; GTR, gross total resection; HGG, high-grade glioma; NOS, not otherwise specified; MT, malignant transformation; NTR, near total resection; PR, partial resection; PXA, pleomorphic xanthoastrocytoma; STR, subtotal resection. 33.33 years). 8 Our study included patients treated at a tertiary referral institution; thus, their risk factors may have differed from those in the population-based study by Krishnatry et al. 8 Our results highlight the importance of long-term surveillance of patients with LGG/LGGNT beyond the traditional 5-year period. The natural history of pediatric
LGGs includes a slowing and sometimes an arrest of tumor growth with time. 3, [20] [21] [22] [23] This has been the basis for using less aggressive therapies and deferring RT in children with LGG in the hope of avoiding potential long-term toxicities. However, it is important not to lose sight of the finding that late progression of the disease and mortality are possible, thus necessitating prolonged follow-up of these patients well into adulthood.
Malignant transformation (MT) of LGG to a high-grade tumor is a well-described phenomenon in children and adults. 10, [24] [25] [26] [27] However, the true incidence of this in children remains to be elucidated.
In our study, 15 patients had documented HGGs, either at progression or autopsy. All of them had a previous histologic confirmation of LGG/LGGNT by biopsy (n = 9), GTR/NTR (n = 3), or STR/PR (n = 3). Glioblastoma was the most common finding at progression; it was present in nine of 15 cases. Only one patient had cancer predisposition in the form of NF-1. In a recent study by Mistry et al., the incidence of MT was 2.6%, 27 and Broniscer et al.
demonstrated a 6.7 ± 3.9% rate of MT of grade II astrocytoma. 10 In our study cohort, we can only hypothesize that among the 15 children with PD-HGG, those with progression at the primary site may have had either a MT or a molecularly high-grade tumor from the outset despite a benign histology, and those with progression at a noncontiguous site had a second malignancy. Due to the lack of molecular data, we are unable to differentiate between these entities with certainty. As demonstrated by Ryall et al., 16 LGGNT.
One of our patients who died in a motor vehicle accident was hit by a drunk driver. We did not have details of the circumstances leading to the deaths of the other two patients. However, one had a history of left-sided superior visual field defects and well-controlled generalized seizures, both of which could potentially result in fatal injuries should the subject be driving a car without appropriate clearance from medical providers. These deaths highlight the importance of multidisciplinary care of these patients to help them reintegrate into society after completing treatment. At St. Jude, patients with limited vision, for example, are sent early to a low-vision clinic and rehabilitation services. 32 In the current era of genomic advances, characterizing the tumor's genetic alterations at diagnosis and progression is invaluable not only for understanding the biology of the tumors but also for prognostication and exploring therapeutic options targeting those changes. Recent studies have demonstrated the role of the MAPK pathway in the pathogenesis of pediatric LGG/LGGNT [33] [34] [35] [36] [37] and molecular changes occurring in childhood HGG. 10, 27 Additionally, reports have suggested that
LGG/LGGNTs with the KIAA1549-BRAF fusion have a better prognosis in comparison to the fusion negative cases 38, 39 and that the presence of BRAFV600E mutation in ganglioglioma is associated with shorter recurrence-free survival in children. 40 Therefore, we must identify the patients who are at the greatest risk of PD and dying of their disease, so that effective therapeutic strategies can be formulated. Our retrospective study is limited, however, by the absence of these molecular data.
CONCLUSIONS
Mortality and its causes in children with LGG/LGGNT is an inadequately studied phenomenon in an otherwise extensively researched pediatric brain tumor. Despite the excellent overall survival, a significant number of affected children die, primarily from PD and in some cases, many years after diagnosis. Children with LGG/LGGNT warrant continued (and in a select few, long-term) monitoring and surveillance.
Our findings help to better delineate these causes and plan therapeutic interventions, including early psychological evaluation and support for vulnerable children and multidisciplinary care for children with
LGG/LGGNT. Molecular characterization of the tumor is emerging as an essential component of the investigative work up of these patients.
